US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
South Korean contract development and manufacturing organization Samsung Biologics says that John Rim will become its president and chief executive, with immediate effect. 17 December 2020
French immunotherapy specialist Transgene said yesterday that its board had approved the appointment of Hedi Ben Brahim as its new chairman and chief executive, effective January 1, 2021. 4 December 2020
UK-based rare diseases specialist Mereo BioPharma today announced the appointment of Dr Suba Krishnan as senior vice president of clinical development, effective December 7, 2020. 23 November 2020
AffaMed Therapeutics today announced a definitive merger agreement with fellow Shanghai, China-based biopharmaceutical company EverInsight Therapeutics. 14 October 2020
Dr Daniel Vasella, former chairman and chief executive of Swiss pharma giant Novartis, has been appointed the new and independent chairman of the board of Swiss biotech Numab Therapeutics. 30 September 2020
David Nicholson, the former executive vice president and chief R&D officer at Allergan, has been named chairman of the board of directors at UK-based Exscientia. 29 September 2020
California, USA-based Nutcracker Therapeutics, a company developing and producing mRNA therapeutics, today announced not only a financing deal but also a new senior executive. 23 September 2020
Privately-held Finnish company Forendo Pharma has announced that Cristina Csimma has been appointed chairwoman of the board of directors. 16 September 2020
US clinical-stage biopharma company Scholar Rock today announced the appointment of Tony Kingsley as president and chief executive, effective August 1, 2020. 14 July 2020
US RNA (mRNA) therapeutics and vaccines specialist Moderna today announced that Ray Jordan has joined the firm as chief corporate affairs officer, effective Monday, June 15, 2020. 16 June 2020
Privately-held German firm Immatics Biotechnologies today announced that Cedrik Britten has been appointed as chief medical officer (CMO) effective June 1, 2020. 4 June 2020
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Clinical-stage USA-based biotech Aruvant Sciences today announced the appointment of V "Palani" Palaniappan, as chief technology officer (CTO) effective immediately. 1 June 2020
French drugmaker Ipsen, which has been under interim management since the surprise departure of its chief executive David Meek in December last year, today announced it has appointed David Loew as its new CEO and as board member. The CEO appointment will take effect on July 1, 2020 29 May 2020